ArticleJournal of virology2005
Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 88 citations in OpenAlex.
- Review
- Coxsackievirus B3-Induced mMicroorganisms · 2024Article
- GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics.Pharmacological research · 2021Review
- Cleavage of Desmosomal Cadherins Promotes γ-Catenin Degradation and Benefits Wnt Signaling in Coxsackievirus B3-Induced Destruction of Cardiomyocytes.Frontiers in microbiology · 2020Article
- Slicing and dicing viruses: antiviral RNA interference in mammals.The EMBO journal · 2019Review
- MicroRNA Expression Profile of Whole Blood Is Altered in Adenovirus-Infected Pneumonia Children.Mediators of inflammation · 2018Article
- Specific interference shRNA-expressing plasmids inhibit Hantaan virus infection in vitro and in vivo.Acta pharmacologica Sinica · 2016Article
- Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis.Virology · 2015Review
- Targeting Highly Structured RNA by Cooperative Action of siRNAs and Helper Antisense Oligomers in Living Cells.PloS one · 2015Article
- Recombinant human coxsackievirus B3 from children with acute myocarditis in China.Journal of clinical microbiology · 2013Article
- Complete genome sequence of a human coxsackievirus b3 from a child with myocarditis in beijing, china.Genome announcements · 2013Article
- Short hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo.BMC infectious diseases · 2012Article
- Progress in targeted delivery of siRNA to combat Coxsackievirus.Protein & cell · 2011Article
- Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.Molecules (Basel, Switzerland) · 2011Review
- Enterovirus infections of the central nervous system.Virology · 2011Review
- Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA.PloS one · 2011Article
- Article
- Exploiting the therapeutic potential of microRNAs in viral diseases: expectations and limitations.Molecular diagnosis & therapy · 2010Review
- Coxsackievirus B3 infection activates the unfolded protein response and induces apoptosis through downregulation of p58IPK and activation of CHOP and SREBP1.Journal of virology · 2010Article
- Control of African swine fever virus replication by small interfering RNA targeting the A151R and VP72 genes.Antiviral therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coxsackievirus B3 (CVB3) is the most common causal agent of viral myocarditis, but existing drug therapies are of limited value. Application of small interfering RNA (siRNA) in knockdown of gene expression is an emerging technology in antiviral gene therapy. To investigate whether RNA interference (RNAi) can protect against CVB3 infection, we evaluated the effects of RNAi on viral replication in HeLa cells and murine cardiomyocytes by using five CVB3-specific siRNAs targeting distinct regions of the viral genome. The most effective one is siRNA-4, targeting the viral protease 2A, achieving a 92% inhibition of CVB3 replication. The specific RNAi effects could last at least 48 h, and cell viability assay revealed that 90% of siRNA-4-pretreated cells were still alive and lacked detectable viral protein expression 48 h postinfection. Moreover, administration of siRNAs after viral infection could also effectively inhibit viral replication, indicating its therapeutic potential. Further evaluation by combination found that no enhanced inhibitory effects were observed when siRNA-4 was cotransfected with each of the other four candidates. In mutational analysis of the mechanisms of siRNA action, we found that siRNA functions by targeting the positive strand of virus and requires a perfect sequence match in the central region of the target, but mismatches were more tolerated near the 3' end than the 5' end of the antisense strand. These findings reveal an effective target for CVB3 silencing and provide a new possibility for antiviral intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.